Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RPS6KA5 | O75582 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | CASP6 | P55212 | 1/20 | 0.34 |
| ▸ | MTOR | P42345 | 1/20 | 0.33 |
| ▸ | TRPV1 | Q8NER1 | 5/20 | 0.33 |
| ▸ | KCNJ1 | P48048 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | EGLN1 | Q9GZT9 | 2/20 | 0.31 |
| ▸ | ALKBH2 | Q6NS38 | 1/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30740344 | 0.80 | TRPV1 (0.39) | RPS6KA5TRPV1EGLN1 | |
| SCHEMBL18298616 | 0.76 | RPS6KA5 (0.38) | RPS6KA5TRPV1EGLN1 | |
| SCHEMBL19100730 | 0.76 | ALDH1A1 (0.41) | RPS6KA5TRPV1ALDH1A1KDM4EMAPK1 | |
| SCHEMBL27905763 | 0.75 | KDM4E (0.37) | RPS6KA5MTORKCNJ1ALDH1A1KDM4E | |
| SCHEMBL28606131 | 0.74 | TRPV1 (0.43) | RPS6KA5TRPV1 | |
| SCHEMBL17670290 | 0.74 | RPS6KA5 (0.35) | RPS6KA5POLBCASP6MTORALDH1A1 | |
| SCHEMBL18298351 | 0.74 | MAPT (0.40) | RPS6KA5TRPV1ALDH1A1SMN1; SMN2GAA | |
| SCHEMBL3146717 | 0.73 | ALKBH2 (0.56) | MTORKCNJ1ALDH1A1KDM4EMAPK1 | |
| SCHEMBL30970909 | 0.73 | ALKBH2 (0.56) | MTORKCNJ1ALDH1A1KDM4EMAPK1 | |
| SCHEMBL18585844 | 0.73 | ALDH1A1 (0.48) | MTORALDH1A1KDM4EEGLN1ALKBH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4725554-A2 | COMPOUNDS AND COMPOSITIONS FOR MODULATING EGFR MUTANT KINASE ACTIVITIES | Yuhan Corporation (KR) | 2026-04-15 | — | — | EP | disclosed |
| US-RE50528-E1 | Compounds and compositions for modulating EGFR mutant kinase activities | YUHAN CORPORATION (KR) | 2025-08-12 | — | — | US | disclosed |
| EP-3929190-B1 | COMPOUNDS AND COMPOSITIONS FOR MODULATING EGFR MUTANT KINASE ACTIVITIES | YUHAN CORP (KR) | 2024-12-25 | — | — | EP | disclosed |
| EP-4421069-A1 | COMPOUNDS AND COMPOSITIONS FOR MODULATING EGFR MUTANT KINASE ACTIVITIES | Yuhan Corporation (KR) | 2024-08-28 | — | — | EP | disclosed |
| CN-111686110-B | Compounds and compositions for modulating EGFR mutant kinase activity | 株式会社柳韩洋行 | 2023-06-16 | — | — | CN | disclosed |
| EP-3929190-A1 | COMPOUNDS AND COMPOSITIONS FOR MODULATING EGFR MUTANT KINASE ACTIVITIES | Yuhan Corporation (KR) | 2021-12-29 | — | — | EP | disclosed |
| EP-3604294-B1 | COMPOUNDS AND COMPOSITIONS FOR MODULATING EGFR MUTANT KINASE ACTIVITIES | YUHAN CORP (KR) | 2021-05-05 | — | — | EP | disclosed |
| CN-111686110-A | Compounds and compositions for modulating EGFR mutant kinase activity | 株式会社柳韩洋行 | 2020-09-22 | — | — | CN | disclosed |
| CN-106795144-B | Compounds and compositions for modulating EGFR mutant kinase activity | 株式会社柳韩洋行 | 2020-06-16 | — | — | CN | disclosed |
| EP-3604294-A1 | COMPOUNDS AND COMPOSITIONS FOR MODULATING EGFR MUTANT KINASE ACTIVITIES | Yuhan Corporation (KR) | 2020-02-05 | — | — | EP | disclosed |
| EP-3207035-B1 | COMPOUNDS AND COMPOSITIONS FOR MODULATING EGFR MUTANT KINASE ACTIVITIES | YUHAN CORP (KR) | 2019-11-20 | — | — | EP | disclosed |
| EP-3207035-A2 | COMPOUNDS AND COMPOSITIONS FOR MODULATING EGFR MUTANT KINASE ACTIVITIES | Yuhan Corporation (KR) | 2017-08-23 | — | — | EP | disclosed |
| CN-106795144-A | Compounds and compositions for modulating EGFR mutant kinase activity | 株式会社柳韩洋行 | 2017-05-31 | — | — | CN | disclosed |
| US-9593098-B2 | Compounds and compositions for modulating EGFR mutant kinase activities | YUHAN CORPORATION (KR) | 2017-03-14 | — | — | US | disclosed |
| WO-2016060443-A2 | COMPOUNDS AND COMPOSITIONS FOR MODULATING EGFR MUTANT KINASE ACTIVITIES | YUHAN CORPORATION (KR) | 2016-04-21 | — | — | WO | disclosed |
| US-20160102076-A1 | COMPOUNDS AND COMPOSITIONS FOR MODULATING EGFR MUTANT KINASE ACTIVITIES | YUHAN CORPORATION | 2016-04-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160102076-A1 | COMPOUNDS AND COMPOSITIONS FOR MODULATING EGFR MUTANT KINASE ACTIVITIES | EGFR, ERBB2, ERBB3 | RPS6KA5 143/4885POLB 2074/4885CASP6 3910/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.